Search results
Results From The WOW.Com Content Network
Over the course of 2023, Lonza continued to pursue its ambitious growth trajectory in a dynamic macroeconomic environment. Our Capital Markets Day in October provided us with a timely
Annual Report. 2023. 2023 was a year of challenge and change, both in the world and at Lonza. We have seen high interest rates, persistent inflation, supply chain disruptions, wars in Ukraine and the Middle East, growing geopolitical tensions, and the continuing challenges of climate change.
All Lonza’s financial and non-financial reports, presentations and key company updates available in the Reporting Center.
Full-Year Report 2023 Small Molecules Division Divisional Overview Small Molecules delivered a strong financial performance in 2023, driven by the division’s continued portfolio shift towards complex and high value small molecules. Compared to Full-Year 2022, the division reported sales growth of 10% (11.2% CER). CORE EBITDA margin increased
Financial Highlights. 2023 was another year of strong performance for Lonza with CHF 6.7 billion sales (7.9% AER; 10.9% CER sales growth) and CHF 2.0 billion CORE EBITDA, resulting in a margin of 29.8%.
At our Capital Markets Day 2023, we announced our new Mid-Term Guidance 2024 – 2028 and confirmed our 2023 Outlook.
This section of our Annual Report provides a short overview of our progress and key achievements relating to the seven SDGs in 2023. It is supported by the 2023 Sustainability Report, which offers more information and insight into our sustainability commitments and our performance indicators.
Creating Value in 2023; Our Businesses; Our Approach to Sustainability; Financial Highlights; Corporate Governance Overview
2023 Highlights; Investor Information; Our Strategic Priorities; Our People and Culture
Annual Report 2023. Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world. Discover more.